Interview with Derek Williams, Vice President and General Manager, Vifor Pharma…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
Address: Flughofstrasse 61, CH-8152 Glattbrugg,Germany
Tel: +41 58 851 80 00
Web: http://www.viforpharma.com/en/
Vifor Pharma is a fully integrated specialty pharma company within the Galenica Group. It unites all companies in the Pharma business sector of Galenica under one single umbrella organisation that researches, develops, produces and markets specific pharmaceutical products throughout the world.It is based on two main pillars: the business units Rx (prescription products) and Consumer Healthcare (OTC products). The operational basis of Vifor Pharma are lean and agile organisational structures. Vifor Pharma enjoys an increasing global presence. While the manufacture of all products is located in Switzerland and in the UK, the commercialisation is taken over by a wide network of affiliates and distributors all over the world.The business unit Vifor Pharma Consumer Healthcare manufactures and markets non-prescription products (OTC products) developed within Vifor Pharma or produced or sold under licence. Vifor Pharma plays a leading role in the area of non-prescription medicines, both in Switzerland and in selected countries of export. The focus of Vifor Pharma Consumer Health is on the development of own structures in key markets in Europe and on the continual optimisation of the product range through own developments and through the acquisition of products, licences and companies.
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
The latest from German pharma, including Bayer’s 2021 financial results, the country’s plan to spend $3.14 billion on vaccine capacity to cover Covid-19 outbreaks until 2029, and Boehringer Ingleheim’s case…
A roundup of the latest news from European biotech, including BioNTech and CureVac’s German vaccine manufacturing deal; the revival of Valneva’s plans to manufacture its vaccine in Scotland; and Morphosys’…
At the recent FT webinar, ‘Supporting Pharma Innovation in Europe’, high-level representatives from Roche, Bayer, and the European Commission weighed in on how European pharma’s competitive position on innovation is…
Building on points developed in his 2020 PharmaBoardroom interview, Professor Nicolaus Kröger of the European Society for Blood and Marrow Transplantation (EBMT) outlines the progress made by the multi-stakeholder GoCART…
In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…
Christian Conrad outlines his role as patient engagement lead for Novartis Oncology in Germany, how individual patient interactions differ from those with advocacy groups, and the current situation for cancer…
After a challenging 2020, and with more hurdles in sight, Bayer has been on an investment spree with a USD 2 billion acquisition of a San Diego-based biotech and manufacturing…
The latest news from German pharma, including Bayer’s USD 2 billion acquisition of San Diego’s Vividion Therapeutics; Boehringer Ingelheim’s new investment in a Vienna production facility; BioNTech’s plans to inaugurate…
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest and most developed nations are represented, other smaller countries are punching…
Writing in the August edition of DIA’s Global Forum, Sanofi R&D’s Thomas Kühler outlines the bumpy journey towards the full adoption of Health Technology Assessment (HTA) across Europe. More…
Boehringer Ingelheim’s Hubertus von Baumbach, the newly appointed president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), shares the goals of his presidency and the role of the…
The latest news from German pharma, including a new US leadership team and more COVID-related investment at Merck KGaA; the CureVac vaccine’s role in fighting COVID-19 variants; and why the…
See our Cookie Privacy Policy Here
